SALT LAKE CITY, April 16, 2020 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq:
CODX) (the Company), a molecular diagnostics company
with a unique, patented platform for the development of molecular
diagnostic tests, announced today that OralDNA® Labs, a
CLIA-certified laboratory, has recently validated a COVID-19 PCR
test based on the Company's patented CoPrimer™ technology for use
with saline oral rinse samples, and has notified the FDA of their
intent to use the validated test in their CAP accredited
high-complexity laboratory.
Dwight Egan, Co-Diagnostics CEO,
remarked, "This validation on the OraRisk® line of
salivary diagnostics showcases the versatility and flexibility of
our CoPrimer platform and COVID-19 test. Saliva specimens are
easily collected with a simple swish and gargle, as opposed to more
invasive collection methods such as nasal swabs. We are pleased
that our technology is being deployed in so many areas in
the United States and countries
across the world, providing the type of quality, high-throughput
diagnostic solutions that many experts agree is the most important
step to curbing the spread of COVID-19 and saving lives."
The Company's Logix Smart™ COVID-19 test is currently available
to all clinical laboratories certified under Clinical Laboratory
Improvement Amendments (CLIA), and is authorized to be used for the
diagnosis of SARS-CoV-2, the virus that causes COVID-19.
OralDNA® Labs' original release may be found
here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company's technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-covid-19-test-technology-validated-for-use-on-saliva-samples-301041709.html
SOURCE Co-Diagnostics